PD173955

• CAT Number: I002889
• CAS Number: 260415-63-2
• Molecular Formula: C21H16Cl2N4OS
• Molecular Weight: 443.35
• Purity: ≥95%
• Target: Bcr-Abl
• Solubility: DMSO: ≥ 32 mg/mL
• Storage: Store at -20 C
• IC50: 22 nM

PD173955 (Cat.No:I002889) is a potent and selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It has shown promise in preclinical studies for its potential as an anticancer agent, particularly against EGFR-dependent tumors. PD173955 is being investigated for its therapeutic applications in various cancer types, including lung and colorectal cancer.

Reference

1:Cancer Res. 2002 Aug 1;62(15):4236-43. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).Nagar B,Bornmann WG,Pellicena P,Schindler T,Veach DR,Miller WT,Clarkson B,Kuriyan J, PMID: 12154025 Abstract: The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia. Small molecule inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia. We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis). Both compounds bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways. As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate. In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase. The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex. In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571. The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.